VSL#3

Phase 2Small molecule

CCD Pharma India Pvt. Ltd.

VSL#3 is one of 118 small molecule programs targeting Hepatic steatosis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

117

Competitors

Pipeline

Status by Indication[3][1]

Indication

Hepatic SteatosisActive, not recruiting

Familial Adenomatous PolyposisActive, not recruiting

DysphagiaActive, not recruiting

EnterocolitisActive, not recruiting

EncephalopathyActive, not recruiting

AsthmaActive, not recruiting

Hepatic SteatosisPhase 1

Active, not recruiting

Familial Adenomatous PolyposisPhase 2

Active, not recruiting

DysphagiaPhase 1

Active, not recruiting

EnterocolitisPhase 2

Active, not recruiting

EncephalopathyPhase 2/Phase 3

Active, not recruiting

AsthmaPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

1050 competitors in Asthma

#DrugCompanyPhaseTrials

Veramyst

GSK

Preclinical

46 2

Xolair

Roche

Preclinical

25 3

VSL#3

CCD Pharma India Pvt. Ltd.

Phase 2

1 4

Dupixent

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

30 5

Celexa

AbbVie

Preclinical

1 6

Arcoxia

Atrovent

2 8

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Preclinical

1 9

Blood Withdrawn

Emergent BioSolutions

Preclinical

1 10

DUPIXENT

Regeneron

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Gulf War Illness2 trials

Probiotic (VSL #3) for Gulf War Illness

Terminated·UUniversity of Utah·Phase 2/3·NCT02011542·29 enrolled

Probiotic (Visbiome) for Gulf War Illness

Unknown status·AAshok Tuteja·Phase 2/3·NCT03078530·60 enrolled

Encephalopathy2 trials

Secondary Prophylaxis of Hepatic Encephalopathy With a Probiotic Preparation

Completed·CCD Pharma India Pvt. Ltd.·Phase 2/3·NCT01110447·130 enrolled

Effect of Probiotics in Treatment of Minimal Hepatic Encephalopathy (MHE) and Health Related Quality of Life

Completed·CCD Pharma India Pvt. Ltd.·Phase 2/3·NCT01008293·120 enrolled

Gastrointestinal1 trial

Changes in Gastrointestinal Microbiota Using VSL#3 in Patients With IBS-D

Unknown status·—·Phase 4·NCT01638208·40 enrolled

Asthma1 trial

Safety of VSL#3 in Adult Asthmatics

Terminated·UUniversity of Maryland, Baltimore·Phase 1/2·NCT00852124·3 enrolled

Postmenopausal Women1 trial

Effect of VSL#3 on Bone Mineral Density in Postmenopausal Women

Terminated·EEmory University·Phase 2·NCT03165747·35 enrolled

9 more indications

Clostridium Difficile1 trial

Probiotics for the Prevention of Antibiotics Associated Diarrhoea and Clostridium Difficile Associated Diarrhoea

Completed·NNational Health Service, United Kingdom·Phase 2/3·NCT00973908·231 enrolled

Crohn's Disease1 trial

VSL#3 Versus Placebo in Maintenance of Remission in Crohn's Disease

Completed·OOrphan Australia·Phase 4·NCT00114465·38 enrolled

Pediatric Patients1 trial

A Prospective, Placebo Controlled, Double-Blind, Cross-over Study on the Effects of a Probiotic Preparation (VSL#3) on Metabolic Profile, Intestinal Permeability, Microbiota, Cytokines and Chemokines Expression and Other Inflammatory Markers in Pediatric Patients With Crohn's Disease

Unknown status·FFederico II University·Phase 4·NCT01632462·30 enrolled

Dysphagia1 trial

Impact of Probiotics on Oral Microbiota in Older Adults With Dysphagia

Completed·UUniversity of Wisconsin, Madison·Phase 1·NCT03682094·9 enrolled

ESS1 trial

Effects of Probiotic VSL#3 on Expression of Small Intestinal Renin-angiotensin System

Completed·GGöteborg University·Phase 1·NCT01635192·24 enrolled

Enterocolitis1 trial

Probiotic Prophylaxis of Hirschprung's Disease Associated Enterocolitis (HAEC)

Completed·UUniversity of Michigan·Phase 2·NCT00630838·62 enrolled

Familial adenomatous polyposis1 trial

Influence of Sulindac and Probiotics on the Development of Pouch Adenomas in Patients With Familial Adenomatous Polyposis

Unknown status·RRadboud University Medical Center·Phase 2·NCT00319007·30 enrolled

Diarrhea1 trial

Dose Ranging Study With the Probiotic Combination (VSL#3) in Diarrhea IBS

Terminated·—·N/A·NCT00179582·180 enrolled

Hepatic steatosis1 trial

The Effect of a Probiotic on Hepatic Steatosis

Terminated·VVSL Pharmaceuticals·Phase 1·NCT00099723·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 16 trial records for VSL#3. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — VSL#3 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for VSL#3. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — CD Pharma India Pvt. Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: CCD Pharma India Pvt. Ltd.

VSL#3

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Gulf War Illness2 trials

Encephalopathy2 trials

Gastrointestinal1 trial

Asthma1 trial

Postmenopausal Women1 trial

Clostridium Difficile1 trial

Crohn's Disease1 trial

Pediatric Patients1 trial

Dysphagia1 trial

ESS1 trial

Enterocolitis1 trial

Familial adenomatous polyposis1 trial

Diarrhea1 trial

Hepatic steatosis1 trial

References

Drug Info

Quick Facts

Related News